SEC Form 5 · accession 0001179110-16-017957
INVIVO THERAPEUTICS HOLDINGS CORP. · NVIV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Ulich
Officer — Chief Scientific Officer
Period of report
Dec 31, 2015
Accepted (ET)
Jan 22, 2016 · 7:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001292519
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 31, 2015 | A | 265 | $6.12 | A | 21,693 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired under the Issuer's Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(d) and Rule 16b-3(c).